Interventional Cardiology

Long-term study shows low incidence of structural valve deterioration after TAVI, guiding clinical care.

Catheter ablation is highly effective for arrhythmias in congenital heart disease patients, French study confirms.

Ten-year data show complete revascularisation reduces repeat procedures in STEMI patients with multivessel disease.

Largest meta-analysis shows no reduction in stroke with routine cerebral embolic protection during TAVI procedures.

Physiology-guided PCI halves major complications after TAVI compared to angiography alone, new FAITAVI trial data show.

Shorter dual antiplatelet therapy followed by low-dose prasugrel cuts bleeding risk after PCI, new trial shows.

Staged TAVI and complex PCI reduce complications compared to combined procedures in patients with severe aortic stenosis.

μQFR shows moderate accuracy for calcified coronary lesions, offering a wire-free FFR alternative.

IVBT lowers major cardiac event rates in multilayer DES-ISR patients compared to standard care over three years.

Final kissing balloon dilatation reduces lesion-specific complications but shows no impact on broader cardiac outcomes in stenting procedures.

PCI for unprotected left main coronary artery shows 70% survival at 5.5 years, according to a 20-year Italian registry of 1,000 patients.

Patients with myeloproliferative neoplasms face higher acute kidney injury and transfusion risks post-PCI, according to a 2.24M hospitalisation study.

New insights from PULSE registry reveal that plug-based closure linked to more TAVI complications than sutures.

Discover how TriClip improves heart function in pacemaker users. Find out why experts are optimistic.

Diabetes raises heart stent risks, but imaging guidance closes outcome gap. Study urges protocol changes.

Study highlights dynamic heart anatomy risks in valve replacement. Imaging key for safer procedures in congenital heart patients.

Study finds elastic compressive dressings are a safe, cost-effective alternative to TR Band after transradial coronary intervention.

Increasing the intensity of physical activity over two months improved anxiety, depression, and fatigue in heart failure patients with ICDs.

PPIs significantly reduce gastrointestinal bleeding risk in AMI patients on DAPT without increasing cardiovascular events. Read more on clinical implications.

First-in-human helical-fixation leadless pacemaker implantation in the left atrium offers a novel solution for congenital heart disease patients.

A decade-long study confirms excellent survival and low reoperation rates for mitral valve repair at high-volume centres.

Women had similar three-year outcomes with FFR-guided PCI and CABG, whereas men had better outcomes with CABG in FAME 3.

ACURATE neo2 TAVI shows strong 30-day outcomes in severe bicuspid aortic stenosis, with high device success and safety.

Coronary events post-TAVR are uncommon but serious. Patients undergoing PCI have better outcomes, especially with balloon-expandable valves.

The Myval THV series is non-inferior to SAPIEN and Evolut THV series at 30 days, offering a promising TAVI alternative.

Polymer-free stents match biodegradable-polymer stents in PCI outcomes but pose a higher early thrombosis risk, requiring careful clinical consideration.

Photon-counting CT outperforms conventional imaging for coronary artery disease, reducing invasive procedures and improving accuracy.

New imaging data show TriClip reduces tricuspid regurgitation and reverses cardiac remodeling, sustaining benefits for one year.

Innovative wearable ACG technology shows promise as a non-invasive diagnostic tool for SLT after TAVR.

Higher rates of bacteraemia and infective endocarditis occur after TAVI compared with CAG, suggesting tailored antibiotic prophylaxis.

SEV and BEV valves with CS or GA yield similar TAVR outcomes; CS lowers mortality and SEVs reduce stroke risk.

Study finds Lipoprotein(a) has no significant impact on aortic valve calcification or mortality in TAVR-treated patients.

LVEF recovery post-PCI differs by CAD presentation, significantly impacting long-term prognosis, particularly in STEMI patients.

PCI plus TAVI offers superior outcomes over SAVR plus CABG for severe aortic stenosis and complex CAD.

K-Clip shows high success rates, improved quality of life, and sustained TR reduction in severe tricuspid regurgitation patients.

3D-Vena Contracta Area (VCA) predicts one-year survival after mitral TEER, guiding better clinical decisions and outcomes.

Clopidogrel reduces thrombotic and bleeding risks over aspirin after PCI, effective regardless of bleeding risk or complexity.

T-TEER improves patient outcomes and quality of life in severe tricuspid regurgitation compared to medical therapy alone.

Bicaval TricValve shows safety, improves symptoms, and reduces hospitalisations in patients with severe tricuspid regurgitation.

The MiCLASP study highlights the PASCAL system’s sustained safety and effectiveness in reducing mitral regurgitation at two years.